Drug intelligence / Profile preview

MSM-608

Development stage: Preclinical
Lead developer: MSM Protein Technologies
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MSM-608 is a monoclonal antibody currently in preclinical development by MSM Medical for the treatment of glioma. The therapeutic candidate is designed to target an undisclosed membrane protein or G protein-coupled receptor (GPCR) associated with the disease. As of the latest company pipeline reports, the program is in the lead optimization stage. While the specific target and downstream signaling effects remain proprietary, the drug represents a targeted biologic approach to addressing high-grade brain tumors.

Beyond the preview

Go deeper on MSM-608.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSM-608.

Explore the full profile